News - Medicago Inc, a Quebec City-based biopharmaceutical company, received a patent from the European Patent Office (EPO) that gives the company sole right to produce flu vaccine-like particles in plants this week.
News - edicago announces the successful production of a Rotavirus VLP vaccine candidate comprising all four structural antigens of rotavirus (VP2, VP4, VP6 and VP7) using Medicago's plant-based manufacturing platform. Medicago also announced today that an international patent application under the Patent Cooperation Treaty (PCT) that broadly covers plant-produced Rotavirus VLPs has been filed.
News - Medicago announces it was granted a patent from the European Patent Office (EPO) providing Medicago the exclusive rights to produce influenza VLPs in plants. Patent Number 2173886, titled "Influenza virus-like particles (VLPs) comprising hemagglutinin produced within a plant", will provide patent coverage for Medicago in Europe through July 2028. The EP 2173886 patent was originally filed on July 11, 2008, and the grant decision is scheduled to be published in the European Patent Bulletin on June 26, 2013.
News - Medicago announces it has received clearance byHealth Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate. All clinical lots have been produced and the trial will commence with interim results expected in the summer of 2013.
News - Medicago reports positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine"). The data show that three micrograms of the H7 vaccine administered with and without adjuvant induced high antibody titers after one dose.
News - According to Génome Québec’s Marie-Kym Brisson, Vice President, Public Affairs and Communications, the partnership between both organizations was the obvious choice: “Genomics has played a major role in the Pierre Lavoie story. It was through genomics, in fact, that the gene responsible for lactic acidosis was identified. Génome Québec has always followed Pierre’s activities closely and we share the values he upholds. This is why we are committed to investing in our community and using our expertise to promote prevention through a healthy lifestyle, an important cause for the future of our society.”
News - DiagnoCure reports that results of a new study were presented on Sunday, June 2, during the 2013 American Society of Clinical Oncology Annual Meeting held in Chicago, Illinois. The abstract of the presentation, by Dr. Daniel J. Sargent, Professor of Biostatistics and Oncology at Mayo Clinic, and colleagues, is now available on the American Society of Clinical Oncology’s website, www.asco.org.
News - Aeterna Zentaris announces that final data for the Phase 1 portion of the ongoing Phase 1/2 trial with its lead oncology compound, zoptarelin doxorubicin (AEZS-108), demonstrated the compound's promising anti-tumor activity in heavily pre treated men with castration- and taxane-resistant prostate cancer. Results were presented earlier today by lead investigator, Jacek Pinski, MD, PhD, of the USC Norris Comprehensive Cancer Center, during a poster session at the American Society of Clinical Oncology's ("ASCO") Annual Meeting in San Francisco.
News - Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of novel, proprietary compounds that target cholinergic receptors for the treatment of pulmonary diseases, today announced that the company will present four posters at the 2013 American Thoracic Society (ATS) International Conference, taking place May 17-22 in Philadelphia. All four will describe data around ASM-024, Asmacure's lead development compound, currently in development for asthma and chronic obstructive pulmonary disease.
News - Medicago announced that it has successfully produced a new VLP vaccine candidate for the H7N9 virus that is responsible for the current influenza outbreak in China. "To our knowledge, Medicago is the first to produce a VLP vaccine candidate against this potential pandemic strain demonstrating our ability to be a first responder in a pandemic scenario," said Andy Sheldon, President and CEO of Medicago.